Peri-procedural myocardial injury during percutaneous coronary intervention: An important target for cardioprotection

European Heart Journal

Volumn 32, Issue 1, 2011, Pages 23-32

  Ganesha Babu, Girish ^a   Malcolm Walker, J ^a   Yellon, Derek M ^a   Hausenloy, Derek J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Ischaemia; Myocardial infarction; Percutaneous coronary intervention; Reperfusion

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CANGRELOR; CLOPIDOGREL; CREATINE KINASE MB; CYCLOSPORIN A; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRULOG; NITRATE; PRASUGREL; PROPRANOLOL; PURINERGIC P2Y12 RECEPTOR; ROSUVASTATIN; THROMBIN ANTITHROMBIN COMPLEX; TICAGRELOR; TICLOPIDINE; TIROFIBAN; TRIMETAZIDINE; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ATHEROMA; CORONARY ARTERY DISEASE; CORONARY STENT; ECG ABNORMALITY; EMBOLISM; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INFLAMMATION; ISCHEMIC PRECONDITIONING; LOADING DRUG DOSE; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PERI PROCEDURAL MYOCARDIUM INJURY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS;

ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; CORONARY VASOSPASM; ELECTROCARDIOGRAPHY; HEART INJURIES; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MAGNETIC RESONANCE ANGIOGRAPHY; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; OXIDATIVE STRESS; PLATELET AGGREGATION; PROGNOSIS; STENTS;

EID: 78651267307     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq393     Document Type: Review

References (134)

1. Cook S, Walker A, Hugli O, Togni M, Meier B. Percutaneous coronary interventions in Europe: prevalence, numerical estimates, and projections based on data up to 2004. Clin Res Cardiol 2007;96:375-382.
2. Moschovitis A, Cook S, Meier B. Percutaneous coronary interventions in Europe in 2006. EuroIntervention 2010;6:189-194.
3. American Heart Association. American Heart Association. Heart Disease and Stroke Statistics-2009 Update. &2009, American Heart Association; 2009.
4. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356: 1503-1516.
5. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1406-1411.
6. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435.
7. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-961.
8. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-1696.
9. PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-443.
10. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, Mahaffey KW, Ohman EM, Teirstein PS, Blankenship JC, Kitt MM, Topol EJ. Clinical outcomes after detection of elevated cardiac enzymes in patients unDergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol 1999;33:88-96.
11. Simoons ML, Van den Brand M, Lincoff M, Harrington R, Van Der Wieken R, Vahanian A, Rutsch W, Kootstra J, Boersma E, Califf RM, Topol E. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J 1999;20:1112-1119.
12. Akkerhuis KM, AlexanDer JH, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, Simoons ML. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002; 105:554-556.
13. Katus HA, Remppis A, Neumann FJ, Scheffold T, DieDerich KW, Vinar G, Noe A, Matern G, Kuebler W. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991;83:902-912.
14. Adams JE III, Sicard GA, Allen BT, Bridwell KH, Lenke LG, Davila-Roman VG, Bodor GS, Ladenson JH, Jaffe AS. Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med 1994;330:670-674.
15. Nienhuis MB, OtterVanger JP, Bilo HJ, Dikkeschei BD, Zijlstra F. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 2008;71:318-324.
16. Bhatt DL, Topol EJ. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 2005;112:906-915.
17. Cutlip DE, Kuntz RE. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. Circulation 2005;112:916-922.
18. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-2538.
19. Testa L, Van Gaal WJ, Biondi Zoccai GG, Agostoni P, Latini RA, Bedogni F, Porto I, Banning AP. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 2009;102:369-378.
20. Pande AK, Meier B, Urban P, Moles V, Dorsaz PA, Favre J. Intracoronary electrocardiogram during coronary angioplasty. Am Heart J 1992;124:337-341.
21. Friedman PL, Shook TL, Kirshenbaum JM, Selwyn AP, Ganz P. Value of the intra-coronary electrocardiogram to monitor myocardial ischemia during percutaneous transluminal coronary angioplasty. Circulation 1986;74:330-339.
22. Balian V, Galli M, Marcassa C, Cecchin G, Child M, Barlocco F, Petrucci E, Filippini G, Michi R, Onofri M. Intracoronary ST-segment shift soon after elective percutaneous coronary intervention accurately predicts periprocedural myocar-dial injury. Circulation 2006;114:1948-1954.
23. Thiele H, Kappl MJ, Conradi S, Niebauer J, Hambrecht R, Schuler G. Reprodu-cibility of chronic and acute infarct size measurement by delayed enhancement-magnetic resonance imaging. J Am Coll Cardiol 2006;47:1641-1645.
24. Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, Parker M, Napoli A, Judd RM. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation 2008;117:629-637.
25. Ingkanisorn WP, Rhoads KL, Aletras AH, Kellman P, Arai AE. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J Am Coll Cardiol 2004;43:2253-2259.
26. SelVanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, Banning AP. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 2005;111:1027-1032.
27. Kim HW, Farzaneh-Far A, Kim RJ. Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. J Am Coll Cardiol 2009;55:1-16.
28. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005; 26:2493-2519.
29. Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR Jr, Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 2006;48:1765-1770.
30. Aliabadi D, Tilli FV, Bowers TR, Benzuly KH, Safian RD, Goldstein JA, Grines CL, O'Neill WW. Incidence and angiographic predictors of side branch occlusion following high-pressure intracoronary stenting. Am J Cardiol 1997;80:994-997.
31. Kralev S, Poerner TC, Basorth D, Lang S, Wolpert C, Haghi D, Borggrefe M, Haase KK, Suselbeck T. Side branch occlusion after coronary stent implantation in patients presenting with ST-elevation myocardial infarction: clinical impact and angiographic predictors. Am Heart J 2006;151:153-157.
32. Vetrovec GW, Cowley MJ, Wolfgang TC, Ducey KC. Effects of percutaneous transluminal coronary angioplasty on lesion-associated branches. Am Heart J 1985;109(5 Pt 1):921-925.
33. Meier B, Gruentzig AR, King SB III, Douglas JS Jr, Hollman J, Ischinger T, Aueron F, Galan K. Risk of side branch occlusion during coronary angioplasty. Am J Cardiol 1984;53:10-14.
34. Poerner TC, Kralev S, Voelker W, Sueselbeck T, Latsch A, Pfleger S, Schumacher B, Borggrefe M, Haase KK. Natural history of small and medium-sized side branches after coronary stent implantation. Am Heart J 2002;143: 627-635.
35. Arora RR, Raymond RE, Dimas AP, Bhadwar K, Simpfendorfer C. Side branch occlusion during coronary angioplasty: incidence, angiographic characteristics, and outcome. Catheter Cardiovasc Diagn 1989;18:210-212.
36. Fallon JT. Pathology of arterial lesions amenable to percutaneous transluminal angioplasty. Am J Roentgenol 1980;135:913-916.
37. Bose D, von Birgelen C, Zhou XY, Schmermund A, Philipp S, Sack S, Konorza T, Mohlenkamp S, Leineweber K, Kleinbongard P, Wijns W, Heusch G, Erbel R. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions. Basic Res Cardiol 2008;103: 587-597.
38. Maehara A, Mintz GS, Weissman NJ. AdVances in intravascular imaging. Circ Car-diovasc Interv 2009;2:482-490.
39. Ahmed JM, Mintz GS, Weissman NJ, Lansky AJ, Pichard AD, Satler LF, Kent KM. Mechanism of lumen enlargement during intracoronary stent implantation: an intravascular ultrasound study. Circulation 2000;102:7-10.
40. Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, Leon MB. Axial plaque redistribution as a mechanism of percutaneous transluminal coronary angio-plasty. Am J Cardiol 1996;77:427-430.
41. Kawamoto T, Okura H, Koyama Y, Toda I, Taguchi H, Tamita K, Yamamuro A, Yoshimura Y, Neishi Y, Toyota E, Yoshida K. The relationship between coronary plaque characteristics and small embolic particles during coronary stent implantation. J Am Coll Cardiol 2007;50:1635-1640.
42. Falk E. Stable versus unstable atherosclerosis: clinical aspects. Am Heart J 1999; 138(5 Pt 2):S421-S425.
43. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the unstable plaque. Prog Cardiovasc Dis 2002;44:349-356.
44. Grube E, Gerckens U, Yeung AC, Rowold S, Kirchhof N, Sedgewick J, Yadav JS, Stertzer S. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 2001;104:2436-2441.
45. Angelini A, Rubartelli P, Mistrorigo F, Della BM, Abbadessa F, Vischi M, Thiene G, Chierchia S. Distal protection with a filter device during coronary stenting in patients with stable and unstable angina. Circulation 2004;110:515-521.
46. Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions : intravascular ultrasound study of 2256 patients. Circulation 2000;101:604-610.
47. Kume T, Akasaka T, Kawamoto T, Okura H, Watanabe N, Toyota E, Neishi Y, Sukmawan R, Sadahira Y, Yoshida K. Measurement of the thickness of the fibrous cap by optical coherence tomography. Am Heart J 2006;152:755.e1-4.
48. Tearney GJ, Yabushita H, Houser SL, Aretz HT, Jang IK, Schlendorf KH, Kauffman CR, Shishkov M, Halpern EF, Bouma BE. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation 2003;107:113-119.
49. Tanaka A, Imanishi T, Kitabata H, Kubo T, Takarada S, Tanimoto T, Kuroi A, Tsujioka H, Ikejima H, Komukai K, Kataiwa H, Okouchi K, Kashiwaghi M, Ishibashi K, Matsumoto H, Takemoto K, Nakamura N, Hirata K, Mizukoshi M, Akasaka T. Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. Eur Heart J 2009;30:1348-1355.
50. Gardner CM, Tan H, Hull EL, Lisauskas JB, Sum ST, Meese TM, Jiang C, Madden SP, Caplan JD, Burke AP, Virmani R, Goldstein J, Muller JE. Detection of lipid core coronary plaques in autopsy specimens with a novel catheter-based near-infrared spectroscopy system. JACC Cardiovasc Imaging 2008;1:638-648.
51. Kereiakes DJ, Gurbel PA. Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. JACC Cardiovasc Interv 2008;1:111-121.
52. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 1987;75:636-642.
53. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90:1614-1621.
54. Gasperetti CM, Gonias SL, Gimple LW, Powers ER. Platelet activation during coronary angioplasty in humans. Circulation 1993;88:2728-2734.
55. Mahemuti A, Meneveau N, Seronde MF, Schiele F, Descotes-Genon V, Ecarnot F, Blonde MC, Mercier M, Racadot E, Bassand JP. Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents. J Thromb Thrombolysis 2009;28:333-341.
56. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, Bali L, Lambert M, Alessi MC, Bonnet JL. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007;97:282-287.
57. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-1126.
58. BonDerman D, Teml A, Jakowitsch J, Adlbrecht C, Gyongyosi M, Sperker W, Lass H, Mosgoeller W, Glogar DH, Probst P, Maurer G, Nemerson Y, Lang IM. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002;99:2794-2800.
59. Mizuno O, Hojo Y, Ikeda U, Katsuki T, Fukazawa H, Kurosaki K, Fujikawa H, Shimada K. Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery. Am J Cardiol 2000;85:154-160.
60. Salloum J, Tharpe C, Vaughan D, Zhao DX. Release and elimination of soluble vasoactive factors during percutaneous coronary intervention of saphenous vein grafts: analysis using the PercuSurge GuardWire distal protection device. J Invasive Cardiol 2005;17:575-579.
61. Fischell TA, Derby G, Tse TM, Stadius ML. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty. A quantitative arteriographic analysis. Circulation 1988;78:1323-1334.
62. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-662.
63. Gregorini L, Marco J, Farah B, Bernies M, Palombo C, Kozakova M, Bossi IM, Cassagneau B, Fajadet J, Di Mario C, Albiero R, Cugno M, Grossi A, Heusch G. Effects of selective alpha1- and alpha2-adrenergic blockade on coronary flow reserve after coronary stenting. Circulation 2002;106:2901-2907.
64. Gregorini L, Marco J, Palombo C, Kozakova M, Anguissola GB, Cassagneau B, Bernies M, Distante A, Marco I, Fajadet J, Zanchetti A. Postischemic left ventricular dysfunction is abolished by alpha-adrenergic blocking agents. J Am Coll Cardiol 1998;31:992-1001.
65. Gregorini L, Marco J, Bernies M, Cassagneau B, Pomidossi G, Anguissola GB, Fajadet J. The alpha-1 adrenergic blocking agent urapidil counteracts postrota-tional atherectomy 'elastic recoil' where nitrates have failed. Am J Cardiol 1997;79:1100-1103.
66. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003;107:2403-2405.
67. Iuliano L, Pratico D, Greco C, Mangieri E, Scibilia G, FitzGerald GA, Violi F. Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 2001;37:76-80.
68. Sanchez-Margalet V, Cubero JM, Martin-Romero C, Cubero J, Cruz-Fernandez JM, Goberna R. Inflammatory response to coronary stent implantation in patients with unstable angina. Clin Chem Lab Med 2002;40: 769-774.
69. Saleh N, SVane B, Jensen J, Hansson LO, Nordin M, Tornvall P. Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris. Am Heart J 2005;149:876-882.
70. Bonz AW, LengenfelDer B, Jacobs M, Strotmann J, Held S, Ertl G, Voelker W. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J 2003; 145:693-699.
71. Gach O, Biemar C, Nys M, Deby-Dupont G, Chapelle JP, Deby C, Lamy M, Pierard LA, Legrand V. Early release of neutrophil markers of activation after direct stenting in patients with unstable angina. Coron Artery Dis 2005;16:59-65.
72. Batchelor WB, Anstrom KJ, Muhlbaier LH, Grosswald R, Weintraub WS, O'Neill WW, Peterson ED. Contemporary outcome trends in the elDerly unDergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. J Am Coll Cardiol 2000;36: 723-730.
73. Kini A, Marmur JD, Kini S, Dangas G, Cocke TP, Wallenstein S, Brown E, Ambrose JA, Sharma SK. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention. J Am Coll Cardiol 1999;34:663-671.
74. Marso SP, Gimple LW, Philbrick JT, DiMarco JP. Effectiveness of percutaneous coronary interventions to prevent recurrent coronary events in patients on chronic hemodialysis. Am J Cardiol 1998;82:378-380.
75. McKechnie RS, Smith D, Montoye C, Kline-Rogers E, O'Donnell MJ, DeFranco AC, Meengs WL, McNamara R, McGinnity JG, Patel K, Share D, Riba A, Khanal S, Moscucci M. Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation 2004;110: 271-277.
76. Goldberg A, Gruberg L, Roguin A, Petcherski S, Rimer D, Markiewicz W, Beyar R, Aronson D. Preprocedural C-reactive protein levels predict myocardial necrosis after successful coronary stenting in patients with stable angina. Am Heart J 2006;151:1265-1270.
77. Gurm HS, Bhatt DL, Gupta R, Ellis SG, Topol EJ, Lauer MS. Preprocedural white blood cell count and death after percutaneous coronary intervention. Am Heart J 2003;146:692-698.
78. Lindahl B, DiDerholm E, Lagerqvist B, Venge P, Wallentin L. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001;38:979-986.
79. Heeschen C, Van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999;100:1509-1514.
80. Benamer H, Steg PG, Benessiano J, Vicaut E, Gaultier CJ, Aubry P, Boudvillain O, Sarfati L, Brochet E, Feldman LJ, Himbert D, Juliard JM, Assayag P. Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina. Am Heart J 1999;137:815-820.
81. Bavry AA, Bhatt DL. Acute Coronary Syndromes in Clinical Practice. Springer-Verlag London Limited; 2009.
82. De Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, BenDermacher PE, Michels HR, SanDers GT, Tijssen JG, Verheugt FW. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005;353:1095-1104.
83. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
84. Van Gaal WJ, Ponnuthurai FA, SelVanayagam J, Testa L, Porto I, Neubauer S, Banning AP. The Syntax score predicts peri-procedural myocardial necrosis during percutaneous coronary intervention. Int J Cardiol 2009;135:60-65.
85. Stone GW, Reifart NJ, Moussa I, Hoye A, Cox DA, Colombo A, Baim DS, Teirstein PS, Strauss BH, Selmon M, Mintz GS, Katoh O, Mitsudo K, Suzuki T, Tamai H, Grube E, Cannon LA, Kandzari DE, Reisman M, Schwartz RS, Bailey S, Dangas G, Mehran R, Abizaid A, Moses JW, Leon MB, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation 2005;112:2530-2537.
86. Roffi M. Percutaneous intervention of saphenous vein grafts. ACC Curr J Rev 2004; 13:45-48.
87. Mautner SL, Mautner GC, Hunsberger SA, Roberts WC. Comparison of composition of atherosclerotic plaques in saphenous veins used as aortocoronary bypass conduits with plaques in native coronary arteries in the same men. Am J Cardiol 1992;70:1380-1387.
88. Roffi M, Mukherjee D. Current role of emboli protection devices in percutaneous coronary and vascular interventions. Am Heart J 2009;157:263-270.
89. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med 1993;329:221-227.
90. Baim DS, Cutlip DE, Sharma SK, Ho KK, Fortuna R, Schreiber TL, Feldman RL, Shani J, Senerchia C, Zhang Y, Lansky AJ, Popma JJ, Kuntz RE. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation 1998;97:322-331.
91. Lefkovits J, Blankenship JC, AnDerson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. J Am Coll Cardiol 1996;28:849-855.
92. Cutlip DE, Leon MB, Ho KK, Gordon PC, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Fitzpatrick MM, Desjardin A, Popma JJ, Kuntz RE, Baim DS. Acute and nine-month clinical outcomes after 'suboptimal' coronary stenting: results from the STent Anti-thrombotic Regimen Study (STARS) registry. J Am Coll Cardiol 1999;34:698-706.
93. Hoole SP, Heck PM, Sharples L, Dutka DP, West NE. Coronary stent length predicts PCI-induced cardiac myonecrosis. Coron Artery Dis 2010;21:312-317.
94. Hildick-Smith D, de BelDer AJ, Cooter N, Curzen NP, Clayton TC, Oldroyd KG, Bennett L, Holmberg S, Cotton JM, Glennon PE, Thomas MR, Maccarthy PA, Baumbach A, Mulvihill NT, HenDerson RA, Redwood SR, Starkey IR, Stables RH. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation 2010;121:1235-1243.
95. Steigen TK, Maeng M, Wiseth R, Erglis A, Kumsars I, Narbute I, Gunnes P, Mannsverk J, Meyerdierks O, Rotevatn S, Niemela M, Kervinen K, Jensen JS, Galloe A, Nikus K, Vikman S, Ravkilde J, James S, Aaroe J, Ylitalo A, Helqvist S, Sjogren I, Thayssen P, Virtanen K, Puhakka M, Airaksinen J, Lassen JF, Thuesen L. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 2006;114:1955-1961.
96. Colombo A, Bramucci E, Sacca S, Violini R, Lettieri C, Zanini R, Sheiban I, Paloscia L, Grube E, Schofer J, Bolognese L, Orlandi M, Niccoli G, Latib A, Airoldi F. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation 2009;119:71-78.
97. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, HenDerson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719.
98. Lembo NJ, Black AJ, Roubin GS, Wilentz JR, Mufson LH, Douglas JS Jr, King SB III. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angio-plasty. Am J Cardiol 1990;65:422-426.
99. King SB III, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, AnDerson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:261-295.
100. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest 2001;119(1 suppl):39S-63S.
101. Hovens MM, Snoep JD, Eikenboom JC, Van Der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007;153:175-181.
102. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100: 1667-1672.
103. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocar-dial infarction in patients unDergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005;111:2099-2106.
104. Weerakkody GJ, Jakubowski JA, Brandt JT, Payne CD, Naganuma H, Winters KJ. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther 2007;12:205-212.
105. Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol 2007;23:963-970.
106. Brown DL, Fann CS, Chang CJ. Meta-analysis of effectiveness and safety of abcix-imab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001;87:537-541.
107. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-1290.
108. Mauri L, Cox D, Hermiller J, Massaro J, Wahr J, Tay SW, Jonas M, Popma JJ, Pavliska J, Wahr D, Rogers C. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. J Am Coll Cardiol 2007;50:1442-1449.
109. Nageh T, Thomas MR, Sherwood RA, Harris BM, Jewitt DE, Wainwright RJ. Direct stenting may limit myocardial injury during percutaneous coronary intervention. J Invasive Cardiol 2003;15:115-118.
110. Cuisset T, Hamilos M, Melikian N, Wyffels E, Sarma J, Sarno G, Barbato E, Bartunek J, Wijns W, De Bruyne B. Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after pre-dilation. J Am Coll Cardiol 2008;51:1060-1065.
111. Burzotta F, Trani C, Prati F, Hamon M, Mazzari MA, Mongiardo R, Sabatier R, Boccanelli A, Schiavoni G, Crea F. Comparison of outcomes (early and six-month) of direct stenting with conventional stenting (a meta-analysis of ten randomized trials). Am J Cardiol 2003;91:790-796.
112. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotec-tion-more than just lipid lowering? Pharmacol Ther 2009;122:30-43.
113. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-678.
114. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A. Novel approaches for preventing or limiting events (Naples) II Trial impact of a single high loading dose of ator-vastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54: 2157-2163.
115. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes unDergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-1278.
116. Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, Yoo NJ, Kim NH, Ahn YK, Jeong JW. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009;137:246-251.
117. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy unDergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54:558-565.
118. Merla R, Reddy NK, Wang FW, Uretsky BF, Barbagelata A, Birnbaum Y. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis. Am J Cardiol 2007;100:770-776.
119. Wang FW, Osman A, Otero J, Stouffer GA, Waxman S, Afzal A, Anzuini A, Uretsky BF. Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation 2003;107:2914-2919.
120. Uretsky BF, Birnbaum Y, Osman A, Gupta R, Paniagua O, Chamoun A, Pohwani A, Lui C, Lev E, McGehee T, Kumar D, Akhtar A, Anzuini A, Schwarz ER, Wang FW. Distal myocardial protection with intracoronary beta blocker when added to a Gp IIb/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome. Catheter Cardiovasc Interv 2008;72:488-497.
121. Leesar MA. Myocardial protection with a beta blocker and glycoprotein IIb/IIIa inhibitor during PCI: attractive concept, but limited evidence of benefit. Catheter Cardiovasc Interv 2008;72:498-499.
122. Di Segni E, Higano ST, Rihal CS, Holmes DR Jr, Lennon R, Lerman A. Incremental doses of intracoronary adenosine for the assessment of coronary velocity reserve for clinical decision making. Catheter Cardiovasc Interv 2001;54:34-40.
123. Desmet WJ, Dens J, Coussement P, Van de WF. Does adenosine prevent myo-cardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. ADEnosine Limit myocardial Necrosis. Heart 2002;88: 293-295.
124. Lee CH, Low A, Tai BC, Co M, Chan MY, Lim J, Lim YT, Tan HC. Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after nonurgent percutaneous coronary intervention: a prospective randomized study. Eur Heart J 2007;28:19-25.
125. Minners J, Van den Bos EJ, Yellon DM, Schwalb H, Opie LH, Sack MN. Dinitro-phenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection. Cardiovasc Res 2000;47:68-73.
126. Bonello L, Sbragia P, Amabile N, Com O, Pierre SV, Levy S, Paganelli F. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 2007;93:703-707.
127. Woodfield K, Ruck A, Brdiczka D, Halestrap AP. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translo-case confirms their role in the mitochondrial permeability transition. Biochem J 1998;336(Pt 2):287-290.
128. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, AngoulVant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481.
129. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
130. Hausenloy DJ. Signalling pathways in ischaemic postconditioning. Thromb Haemost 2009;101:626-634.
131. Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation 1999;99:2085-2089.
132. Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, Densem CG, Clarke SC, Shapiro LM, Schofield PM, O'SulliVan M, Dutka DP. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation 2009;119:820-827.
133. Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM. Effect of remote ischaemic preconditioning on myocardial injury in patients unDergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 2007;370(11 suppl):575-579.
134. Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, Boyle JR, Varty K, Kharbanda RK, Dutka DP, Gaunt ME. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation 2007;116:I98-I105.